{"success":true,"data":{"pressRelease":{"id":"155089","rtpr_id":"nNFCGqBZC-20260929","ticker":"BHST","exchange":"NASDAQ","all_tickers":["BHST"],"title":"BioHarvest Sciences Announces Share Repurchase Program","author":"Newsfile Corp","published_at":"2026-09-29T11:00:16.972Z","article_body":"Vancouver, British Columbia and Rehovot, Israel--(Newsfile Corp. - September\n29, 2026) - BioHarvest Sciences Inc.\n(https://api.newsfilecorp.com/redirect/0p08MHw0Ag) (NASDAQ: BHST) (TASE: BHST)\n(FSE: 8MV0) (\"BioHarvest\" or the \"Company\"), a Botanical Synthesis company\ndeveloping and manufacturing proprietary plant-based compositions for\ncustomers, partners and its own portfolio, announced today that its Board of\nDirectors has authorized a share repurchase program, structured in accordance\nwith Canadian practices as a normal course issuer bid (the \"NCIB\").\n\nThe Company's Board of Directors believes that the market price of the Common\nShares may not fully reflect the underlying value of the Company's business\nand future growth prospects. Consequently, the Board believes that adding the\nflexibility to strategically repurchase Common Shares represents an\nadvantageous and effective allocation of capital that is in the best interests\nof the Company and its shareholders.\n\nDr. Zaki Rakib, Chief Executive Officer and Executive Chairman of BioHarvest\nSciences commented, \"We believe BioHarvest today is a substantially different\ncompany from the one reflected in our current market valuation. We have\nevolved from a company built primarily around VINIA into a technology-driven\ncompany with a proprietary Botanical Synthesis platform capable of developing\nand manufacturing multiple high-value plant-derived molecules across various\nindustries. Programs in natural sweeteners, rare fragrances and other\nhigh-value compounds are advancing toward commercialization, creating the\npotential for manufacturing revenues and royalties in addition to our existing\nVINIA business, which itself represents a meaningful asset with significant\noperating leverage as it scales.\n\nWe believe the market has yet to fully recognize this transformation and the\nvalue of the assets we have built. With disciplined cash management and\ncomplete confidence in our long-term outlook, the board concluded that at\ncurrent valuation levels, purchasing our own shares represents an attractive\nuse of capital. In simple terms, we are investing in the asset we know\nbest-BioHarvest.\"\n\nUnder the terms of the NCIB, the Company will purchase up to 5% of its\noutstanding common shares (the maximum percentage allowed in any 12-month\nperiod under a normal course issuer bid), equating to a maximum of 1,133,392\nshares. The NCIB will not commence earlier than 5 days following this\nannouncement and will terminate on the earlier of: (i) 12 months from the\nstart of the NCIB (ii) the date on which the maximum number of Common Shares\nauthorized under the NCIB have been purchased, or (iii) the date on which the\nNCIB is earlier terminated at the option of the Company.\n\nAll purchases made under the NCIB will be executed through the facilities of\nNasdaq Stock Market (\"Nasdaq\") in accordance with Rule 10b-18 under the U.S.\nSecurities Exchange Act of 1934, as amended, and in such a manner to satisfy\nthe safe harbor requirements of Rule 10b-18.\n\nPurchases will be made by the Company in the open market at prevailing market\nprices at the time of acquisition. The actual number of Common Shares\nrepurchased, the timing of any repurchases, and the price at which they are\nbought will be determined at the discretion of management, subject to\napplicable securities laws. All Common Shares repurchased under the NCIB will\nbe retired.\n\nAbout BioHarvest Sciences Inc.\n\nBioHarvest Sciences Inc. (NASDAQ: BHST) (TASE: BHST) (FSE: 8MV0) is a\nBotanical Synthesis company leveraging its proprietary technology platform to\ndevelop and manufacture plant-based compositions without growing the\nunderlying plant. Through Botanical Synthesis, BioHarvest produces consistent,\nfull-spectrum plant compound compositions designed for commercial use across\nconsumer and partner applications, advancing BioHarvest's mission to provide\nnatural wellness at scale.\n\nThe Company is increasingly focused on applying its Botanical Synthesis\ncapabilities as a Contract Development and Manufacturing Organization (CDMO),\npartnering with customers to develop, scale, and manufacture valuable\nplant-based compositions across multiple industries. BioHarvest combines\nplant-cell biology, process development, and scaled manufacturing to provide\npartners with a path from plant cells to commercially viable compositions.\n\nBioHarvest also owns proprietary assets developed through its Botanical\nSynthesis platform, including VINIA®, its first consumer product from\nBotanical Synthesis and commercially established red-grape cell composition.\nThese proprietary assets provide BioHarvest with additional opportunities for\nvalue creation while demonstrating the commercial capabilities of its\ntechnology platform.\n\nTo learn more, please visit www.bioharvest.com.\n\nForward-Looking Statements\n\nInformation set forth in this news release might include forward-looking\nstatements that are based on management's current estimates, beliefs,\nintentions, and expectations, and are subject to a number of risks and\nuncertainties that could cause actual results to differ materially from those\ndescribed in the forward-looking statements. The forward-looking statements\nherein relate to the Company's intention to commence the NCIB; the timing,\nquantity and funding of any purchases of common shares under the NCIB; the\nexpected facilities through which any such purchases may be made; and other\nmatters.\n\nWhile management believes these forward-looking statements to be reasonable\nunder the circumstances, they may prove to be inaccurate. These\nforward-looking statements are subject to risks and uncertainties and are\nbased on assumptions that may cause future results to differ materially from\nthose expected. The material assumptions made in making these forward-looking\nstatements include the following: the Company's view with respect to its\nfinancial condition and prospects; the stability of general economic and\nmarket conditions and currency exchange rates; the availability of cash\nresources for repurchases of outstanding common shares under the NCIB; the\nexistence of potentially superior uses for the Company's cash resources than\ncommon share repurchases; a reduction in the size of the Company's \"public\nfloat\" as a result of repurchases made under the NCIB, compliance with\napplicable laws and regulations pertaining to the BCIB; that the Company will\ncontinue to have sufficient financial resources to fund currently anticipated\nfinancial actions and obligations and to pursue desirable business\nopportunities.\n\nForward-looking statements are provided for the purpose of providing\ninformation about management's current expectations and plans relating to the\nfuture. Readers are cautioned that such information may not be appropriate for\nother purposes. The above list is not exhaustive of the factors that may\naffect any of the Company's forward-looking information. You should not place\nundue reliance on forward-looking information and statements. Forward-looking\ninformation and statements are only predictions based on our current\nexpectations and the Company's projections about future events. Actual results\nmay vary from such forward-looking information for a variety of reasons\nincluding, but not limited to, risks and uncertainties disclosed in our\nfilings on our website at https://bioharvest.com/, on SEDAR+ at\nwww.sedarplus.ca, and on EDGAR at www.sec.gov and other unforeseen events or\ncircumstances. Other than as required by law, we do not intend, and undertake\nno obligation to update any forward-looking information to reflect, among\nother things, new information or future events. The information contained on,\nor that may be accessed through, our website is not incorporated by reference\ninto, and is not a part of, this document.\n\nBioHarvest Corporate Contact:\nDave Ryan, VP Investor Relations\n+1 (604) 622-1186\ninfo@bioharvest.com\n\nInvestor Relations Contact:\nChuck Padala, Managing Director\nLifeSci Advisors\nchuck@lifesciadvisors.com\n\n\nTo view the source version of this press release, please visit\nhttps://www.newsfilecorp.com/release/316501","article_body_html":"","raw_payload":{"data":{"id":"nNFCGqBZC-20260929","title":"BioHarvest Sciences Announces Share Repurchase Program","author":"Newsfile Corp","ticker":"BHST","created":"2026-09-29T11:00:16.972Z","tickers":["BHST"],"exchange":"NASDAQ","article_body":"Vancouver, British Columbia and Rehovot, Israel--(Newsfile Corp. - September\n29, 2026) - BioHarvest Sciences Inc.\n(https://api.newsfilecorp.com/redirect/0p08MHw0Ag) (NASDAQ: BHST) (TASE: BHST)\n(FSE: 8MV0) (\"BioHarvest\" or the \"Company\"), a Botanical Synthesis company\ndeveloping and manufacturing proprietary plant-based compositions for\ncustomers, partners and its own portfolio, announced today that its Board of\nDirectors has authorized a share repurchase program, structured in accordance\nwith Canadian practices as a normal course issuer bid (the \"NCIB\").\n\nThe Company's Board of Directors believes that the market price of the Common\nShares may not fully reflect the underlying value of the Company's business\nand future growth prospects. Consequently, the Board believes that adding the\nflexibility to strategically repurchase Common Shares represents an\nadvantageous and effective allocation of capital that is in the best interests\nof the Company and its shareholders.\n\nDr. Zaki Rakib, Chief Executive Officer and Executive Chairman of BioHarvest\nSciences commented, \"We believe BioHarvest today is a substantially different\ncompany from the one reflected in our current market valuation. We have\nevolved from a company built primarily around VINIA into a technology-driven\ncompany with a proprietary Botanical Synthesis platform capable of developing\nand manufacturing multiple high-value plant-derived molecules across various\nindustries. Programs in natural sweeteners, rare fragrances and other\nhigh-value compounds are advancing toward commercialization, creating the\npotential for manufacturing revenues and royalties in addition to our existing\nVINIA business, which itself represents a meaningful asset with significant\noperating leverage as it scales.\n\nWe believe the market has yet to fully recognize this transformation and the\nvalue of the assets we have built. With disciplined cash management and\ncomplete confidence in our long-term outlook, the board concluded that at\ncurrent valuation levels, purchasing our own shares represents an attractive\nuse of capital. In simple terms, we are investing in the asset we know\nbest-BioHarvest.\"\n\nUnder the terms of the NCIB, the Company will purchase up to 5% of its\noutstanding common shares (the maximum percentage allowed in any 12-month\nperiod under a normal course issuer bid), equating to a maximum of 1,133,392\nshares. The NCIB will not commence earlier than 5 days following this\nannouncement and will terminate on the earlier of: (i) 12 months from the\nstart of the NCIB (ii) the date on which the maximum number of Common Shares\nauthorized under the NCIB have been purchased, or (iii) the date on which the\nNCIB is earlier terminated at the option of the Company.\n\nAll purchases made under the NCIB will be executed through the facilities of\nNasdaq Stock Market (\"Nasdaq\") in accordance with Rule 10b-18 under the U.S.\nSecurities Exchange Act of 1934, as amended, and in such a manner to satisfy\nthe safe harbor requirements of Rule 10b-18.\n\nPurchases will be made by the Company in the open market at prevailing market\nprices at the time of acquisition. The actual number of Common Shares\nrepurchased, the timing of any repurchases, and the price at which they are\nbought will be determined at the discretion of management, subject to\napplicable securities laws. All Common Shares repurchased under the NCIB will\nbe retired.\n\nAbout BioHarvest Sciences Inc.\n\nBioHarvest Sciences Inc. (NASDAQ: BHST) (TASE: BHST) (FSE: 8MV0) is a\nBotanical Synthesis company leveraging its proprietary technology platform to\ndevelop and manufacture plant-based compositions without growing the\nunderlying plant. Through Botanical Synthesis, BioHarvest produces consistent,\nfull-spectrum plant compound compositions designed for commercial use across\nconsumer and partner applications, advancing BioHarvest's mission to provide\nnatural wellness at scale.\n\nThe Company is increasingly focused on applying its Botanical Synthesis\ncapabilities as a Contract Development and Manufacturing Organization (CDMO),\npartnering with customers to develop, scale, and manufacture valuable\nplant-based compositions across multiple industries. BioHarvest combines\nplant-cell biology, process development, and scaled manufacturing to provide\npartners with a path from plant cells to commercially viable compositions.\n\nBioHarvest also owns proprietary assets developed through its Botanical\nSynthesis platform, including VINIA®, its first consumer product from\nBotanical Synthesis and commercially established red-grape cell composition.\nThese proprietary assets provide BioHarvest with additional opportunities for\nvalue creation while demonstrating the commercial capabilities of its\ntechnology platform.\n\nTo learn more, please visit www.bioharvest.com.\n\nForward-Looking Statements\n\nInformation set forth in this news release might include forward-looking\nstatements that are based on management's current estimates, beliefs,\nintentions, and expectations, and are subject to a number of risks and\nuncertainties that could cause actual results to differ materially from those\ndescribed in the forward-looking statements. The forward-looking statements\nherein relate to the Company's intention to commence the NCIB; the timing,\nquantity and funding of any purchases of common shares under the NCIB; the\nexpected facilities through which any such purchases may be made; and other\nmatters.\n\nWhile management believes these forward-looking statements to be reasonable\nunder the circumstances, they may prove to be inaccurate. These\nforward-looking statements are subject to risks and uncertainties and are\nbased on assumptions that may cause future results to differ materially from\nthose expected. The material assumptions made in making these forward-looking\nstatements include the following: the Company's view with respect to its\nfinancial condition and prospects; the stability of general economic and\nmarket conditions and currency exchange rates; the availability of cash\nresources for repurchases of outstanding common shares under the NCIB; the\nexistence of potentially superior uses for the Company's cash resources than\ncommon share repurchases; a reduction in the size of the Company's \"public\nfloat\" as a result of repurchases made under the NCIB, compliance with\napplicable laws and regulations pertaining to the BCIB; that the Company will\ncontinue to have sufficient financial resources to fund currently anticipated\nfinancial actions and obligations and to pursue desirable business\nopportunities.\n\nForward-looking statements are provided for the purpose of providing\ninformation about management's current expectations and plans relating to the\nfuture. Readers are cautioned that such information may not be appropriate for\nother purposes. The above list is not exhaustive of the factors that may\naffect any of the Company's forward-looking information. You should not place\nundue reliance on forward-looking information and statements. Forward-looking\ninformation and statements are only predictions based on our current\nexpectations and the Company's projections about future events. Actual results\nmay vary from such forward-looking information for a variety of reasons\nincluding, but not limited to, risks and uncertainties disclosed in our\nfilings on our website at https://bioharvest.com/, on SEDAR+ at\nwww.sedarplus.ca, and on EDGAR at www.sec.gov and other unforeseen events or\ncircumstances. Other than as required by law, we do not intend, and undertake\nno obligation to update any forward-looking information to reflect, among\nother things, new information or future events. The information contained on,\nor that may be accessed through, our website is not incorporated by reference\ninto, and is not a part of, this document.\n\nBioHarvest Corporate Contact:\nDave Ryan, VP Investor Relations\n+1 (604) 622-1186\ninfo@bioharvest.com\n\nInvestor Relations Contact:\nChuck Padala, Managing Director\nLifeSci Advisors\nchuck@lifesciadvisors.com\n\n\nTo view the source version of this press release, please visit\nhttps://www.newsfilecorp.com/release/316501"},"type":"article","timestamp":"2026-09-29T11:00:17.04166474Z","server_sent_at_ms":1790679617041},"received_at":"2026-09-29T11:00:17.093Z","source_url":"https://www.newsfilecorp.com/release/316501"},"analysis":{"id":"143827","press_release_id":"155089","analysis_json":{"industry":{"label":"Pharmaceuticals, Biotechnology & Life Sciences","sector":"Health Care"},"redFlags":[],"eventType":"buyback","narrative":"BioHarvest Sciences' board authorized a normal course issuer bid to repurchase up to 5% of outstanding common shares, a maximum of 1,133,392 shares over 12 months.\n\nPurchases will be made in the open market on Nasdaq under Rule 10b-18 safe-harbor provisions at management's discretion, with repurchased shares retired.\n\nCEO Dr. Zaki Rakib argued the market undervalues the company's transformation from its VINIA consumer product into a Botanical Synthesis CDMO platform with programs in natural sweeteners and rare fragrances advancing toward commercialization.","sentiment":"bullish","agentHooks":{"shouldPost":false,"suggestedAngle":"Small-cap signals undervaluation with a 5% NCIB buyback authorization."},"keyFigures":{"customDimensions":{"ncib_term":"12 months","max_shares":1133392,"max_repurchase_pct":"5%"}},"quotedText":"In simple terms, we are investing in the asset we know best-BioHarvest.","namedEntities":{"people":[{"name":"Dr. Zaki Rakib","role":"CEO and Executive Chairman"},{"name":"Dave Ryan","role":"VP Investor Relations"},{"name":"Chuck Padala","role":"Managing Director, LifeSci Advisors"}],"products":["VINIA"],"companies":[{"name":"BioHarvest Sciences Inc.","ticker":"BHST","relationship":"filer"},{"name":"LifeSci Advisors","relationship":"investor relations firm"}],"dollarAmounts":[]},"materialImpact":{"score":2,"reasoning":"Board authorized a NCIB to repurchase up to 5% of outstanding shares (max 1,133,392 shares). A routine small-cap buyback authorization without stated dollar size or accel buyback."},"tickerRelevance":{"others":[],"primary":"BHST"},"globalImportance":20,"audienceRelevance":15,"eventTypeSecondary":[],"importanceComponents":{"tickerTier":"small-cap","eventGravity":"routine NCIB authorization","eventSpecificity":"no dollar size disclosed","retailFavoriteBoost":false}},"event_type":"buyback","event_type_secondary":null,"sentiment":"bullish","material_impact_score":2,"narrative":"BioHarvest Sciences' board authorized a normal course issuer bid to repurchase up to 5% of outstanding common shares, a maximum of 1,133,392 shares over 12 months.\n\nPurchases will be made in the open market on Nasdaq under Rule 10b-18 safe-harbor provisions at management's discretion, with repurchased shares retired.\n\nCEO Dr. Zaki Rakib argued the market undervalues the company's transformation from its VINIA consumer product into a Botanical Synthesis CDMO platform with programs in natural sweeteners and rare fragrances advancing toward commercialization.","key_figures":{"customDimensions":{"ncib_term":"12 months","max_shares":1133392,"max_repurchase_pct":"5%"}},"named_entities":{"people":[{"name":"Dr. Zaki Rakib","role":"CEO and Executive Chairman"},{"name":"Dave Ryan","role":"VP Investor Relations"},{"name":"Chuck Padala","role":"Managing Director, LifeSci Advisors"}],"products":["VINIA"],"companies":[{"name":"BioHarvest Sciences Inc.","ticker":"BHST","relationship":"filer"},{"name":"LifeSci Advisors","relationship":"investor relations firm"}],"dollarAmounts":[]},"model_name":"glm-5.3-flashx","prompt_hash":"sha256:727b4b9429a443af","schema_hash":"sha256:05005c02d9cffac9","created_at":"2026-09-29T11:00:28.898Z","global_importance":20,"audience_relevance":15,"importance_components":{"tickerTier":"small-cap","eventGravity":"routine NCIB authorization","eventSpecificity":"no dollar size disclosed","retailFavoriteBoost":false}},"durationMs":5229,"modelName":"glm-5.3-flashx"}}